{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T04:43:04Z","timestamp":1778042584796,"version":"3.51.4"},"reference-count":35,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T00:00:00Z","timestamp":1668470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Antiblastic drugs-induced cardiomyopathy remains a relevant cause of morbidity and mortality, during and after chemotherapy, despite the progression in protective therapy against cardiovascular diseases and myocardial function. In the last few decades, many groups of researchers have focused their attention on studying the metabolic profile, first in animals, and, subsequently, in humans, looking for profiles which could be able to predict drug-induced cardiotoxicity and cardiovascular damage. In clinical practice, patients identified as being at risk of developing cardiotoxicity undergo a close follow-up and more tailored therapies. Injury to the heart can be a consequence of both new targeted therapies, such as tyrosine kinase inhibitors, and conventional chemotherapeutic agents, such as anthracyclines. This review aims to describe all of the studies carried on this topic of growing interest.<\/jats:p>","DOI":"10.3390\/jcm11226745","type":"journal-article","created":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T02:32:16Z","timestamp":1668479536000},"page":"6745","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Metabolomic Profiles on Antiblastic Cardiotoxicity: New Perspectives for Early Diagnosis and Cardioprotection"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2407-7435","authenticated-orcid":false,"given":"Luca","family":"Fazzini","sequence":"first","affiliation":[{"name":"Department of Medical Sciences and Public Health, University Hospital of Cagliari, Strada Statale 554, Km 4.500, 09042 Monserrato, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludovica","family":"Caggiari","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences and Public Health, University Hospital of Cagliari, Strada Statale 554, Km 4.500, 09042 Monserrato, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3725-7614","authenticated-orcid":false,"given":"Martino","family":"Deidda","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences and Public Health, University Hospital of Cagliari, Strada Statale 554, Km 4.500, 09042 Monserrato, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlotta","family":"Onnis","sequence":"additional","affiliation":[{"name":"Department of Radiology, Azienda Ospedaliero Universitaria (A.O.U.), di Cagliari\u2014Polo di Monserrato, Strada Statale 554, 09042 Monserrato, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Saba","sequence":"additional","affiliation":[{"name":"Department of Radiology, Azienda Ospedaliero Universitaria (A.O.U.), di Cagliari\u2014Polo di Monserrato, Strada Statale 554, 09042 Monserrato, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Mercuro","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences and Public Health, University Hospital of Cagliari, Strada Statale 554, Km 4.500, 09042 Monserrato, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2823-1797","authenticated-orcid":false,"given":"Christian","family":"Cadeddu Dessalvi","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences and Public Health, University Hospital of Cagliari, Strada Statale 554, Km 4.500, 09042 Monserrato, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s10741-016-9564-5","article-title":"Current views on anthracycline cardiotoxicity","volume":"21","author":"Mele","year":"2016","journal-title":"Heart Fail. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.2459\/JCM.0000000000000376","article-title":"Pathophysiology of cardiotoxicity induced by non-anthracycline chemotherapy","volume":"17","author":"Madeddu","year":"2016","journal-title":"J. Cardiovasc. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1136\/postgradmedj-2016-134417","article-title":"Cardiovascular disease in cancer survivors","volume":"93","author":"Okwuosa","year":"2017","journal-title":"Postgrad. Med. J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s10549-022-06515-5","article-title":"Trends in heart disease mortality among breast cancer survivors in the US, 1975\u20132017","volume":"192","author":"Vo","year":"2022","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1634\/theoncologist.12-9-1124","article-title":"Early epirubicin-induced myocardial dysfunction revealed by serial tissue doppler echocardiography: Correlation with inflammatory and oxidative stress markers","volume":"12","author":"Mercuro","year":"2007","journal-title":"Oncologist"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Deidda, M., Mercurio, V., Cuomo, A., Noto, A., Mercuro, G., and Cadeddu Dessalvi, C. (2019). Metabolomic Perspectives in Antiblastic CardiotoxiCity and Cardioprotection. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20194928"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"D801","DOI":"10.1093\/nar\/gks1065","article-title":"HMDB 3.0\u2014The human metabolome database in 2013","volume":"41","author":"Wishart","year":"2013","journal-title":"Nucl. Acids Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"D603","DOI":"10.1093\/nar\/gkn810","article-title":"HMDB: A knowledgebase for the human metabolome","volume":"37","author":"Wishart","year":"2009","journal-title":"Nucl. Acids Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/nbm.1370","article-title":"Metabonomic identification of novel biomarkers in doxorubicin cardiotoxicity and protective effect of the natural antioxidant oleuropein","volume":"22","author":"Andreadou","year":"2009","journal-title":"NMR Biomed."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.yjmcc.2014.01.007","article-title":"Oleuropein prevents doxorubicin-induced cardiomyopathy interfering with signaling molecules and cardiomyocyte metabolism","volume":"69","author":"Andreadou","year":"2014","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Tan, G., Lou, Z., Liao, W., Zhu, Z., Dong, X., Zhang, W., Li, W., and Chai, Y. (2011). Potential biomarkers in mouse myocardium of doxorubicin-induced cardiomyopathy: A metabolomic method and its application. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0027683"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.talanta.2011.11.071","article-title":"Metabonomic study on the cumulative cardiotoxicity of a pirarubicin liposome powder","volume":"89","author":"Cong","year":"2012","journal-title":"Talanta"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1021\/pr501116c","article-title":"Screening, verification, and optimization of biomarkers for early prediction of cardiotoxicity based on metabolomics","volume":"14","author":"Li","year":"2015","journal-title":"J. Proteome Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/jat.3307","article-title":"Early metabolomics changes in heart and plasma during chronic doxorubicin treatment in B6C3F1 mice","volume":"36","author":"Schnackenberg","year":"2016","journal-title":"J. Appl. Toxicol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jchromb.2016.08.042","article-title":"Plasma metabolic profiling analysis of cyclophosphamide-induced cardiotoxicity using metabolomics coupled with UPLC\/Q-TOF-MS and ROC curve","volume":"1033","author":"Yin","year":"2016","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1007\/s00726-017-2419-0","article-title":"Metabolite signatures of doxorubicin induced toxicity in human induced pluripotent stem cell-derived cardiomyocytes","volume":"49","author":"Chaudhari","year":"2017","journal-title":"Amino Acids"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"QuanJun, Y., GenJin, Y., LiLi, W., YongLong, H., Yan, H., Jie, L., JinLu, H., Jin, L., Run, G., and Cheng, G. (2017). Protective effects of dexrazoxane against doxorubicin-induced cardiotoxicity: A metabolomic study. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0169567"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"732554","DOI":"10.3389\/fcvm.2021.732554","article-title":"Periplocymarin Alleviates Doxorubicin-Induced Heart Failure and Excessive Accumulation of Ceramides","volume":"8","author":"Yun","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/s42003-020-01440-z","article-title":"Early detection of doxorubicin-induced cardiotoxicity in rats by its cardiac metabolic signature assessed with hyperpolarized MRI","volume":"3","author":"Timm","year":"2020","journal-title":"Commun. Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"782745","DOI":"10.3389\/fphys.2021.782745","article-title":"Metabolic Effects of Doxorubicin on the Rat Liver Assessed With Hyperpolarized MRI and Metabolomics","volume":"12","author":"Timm","year":"2022","journal-title":"Front. Physiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1021\/acsomega.0c04677","article-title":"Systematic Evaluations of Doxorubicin-Induced Toxicity in Rats Based on Metabolomics","volume":"6","author":"Geng","year":"2020","journal-title":"ACS Omega"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/jrr\/rrz079","article-title":"Metabolic changes in mice cardiac tissue after low-dose irradiation revealed by 1H NMR spectroscopy","volume":"61","author":"Gramatyka","year":"2020","journal-title":"J. Radiat. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"113045","DOI":"10.1016\/j.jpba.2019.113045","article-title":"Metabolic profiling of tyrosine kinase inhibitor nintedanib using metabolomics","volume":"180","author":"Zhou","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e008220","DOI":"10.1161\/CIRCHEARTFAILURE.120.008220","article-title":"Yellow Wine Polyphenolic Compound Protects Against Doxorubicin-Induced Cardiotoxicity by Modulating the Composition and Metabolic Function of the Gut Microbiota","volume":"14","author":"Lin","year":"2021","journal-title":"Circ. Heart Fail."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"173229","DOI":"10.1016\/j.ejphar.2020.173229","article-title":"The protective effect of losartan against sorafenib induced cardiotoxicity: Ex-vivo isolated heart and metabolites profiling studies in rat","volume":"882","author":"Abdelgalil","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e22842","DOI":"10.1002\/jbt.22842","article-title":"Protective effect of valsartan against doxorubicin-induced cardiotoxicity: Histopathology and metabolomics in vivo study","volume":"35","author":"Alhazzani","year":"2021","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Yoon, C.S., Kim, H.K., Mishchenko, N.P., Vasileva, E.A., Fedoreyev, S.A., Stonik, V.A., and Han, J. (2018). Spinochrome D Attenuates Doxorubicin-Induced Cardiomyocyte Death via Improving Glutathione Metabolism and Attenuating Oxidative Stress. Mar. Drugs, 17.","DOI":"10.3390\/md17010002"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/toxsci\/kfaa015","article-title":"A Targeted Metabolomics-Based Assay Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Identifies Structural and Functional Cardiotoxicity Potential","volume":"174","author":"Palmer","year":"2020","journal-title":"Toxicol. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Draguet, A., Tagliatti, V., and Colet, J.M. (2021). Targeting Metabolic Reprogramming to Improve Breast Cancer Treatment: An In Vitro Evaluation of Selected Metabolic Inhibitors Using a Metabolomic Approach. Metabolites, 11.","DOI":"10.3390\/metabo11080556"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00204-021-03204-y","article-title":"Cardiotoxicity of cyclophosphamide\u2019s metabolites: An in vitro metabolomics approach in AC16 human cardiomyocytes","volume":"96","author":"Bastos","year":"2022","journal-title":"Arch. Toxicol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.radonc.2020.04.018","article-title":"Plasma metabolite biomarkers predictive of radiation induced cardiotoxicity","volume":"152","author":"Unger","year":"2020","journal-title":"Radiother. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s12265-019-09897-y","article-title":"Changes in Citric Acid Cycle and Nucleoside Metabolism Are Associated with Anthracycline Cardiotoxicity in Patients with Breast Cancer","volume":"13","author":"Asnani","year":"2020","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"ehaa946.3289","DOI":"10.1093\/ehjci\/ehaa946.3289","article-title":"University of Cagliari, Italy, Defining the metabolomic profile associated with early cardiotoxicity in patients with breast cancer treated with anthracyclines","volume":"41","author":"Cocco","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ijcard.2015.04.232","article-title":"Cardioprotection by gene therapy: A review paper on behalf of the Working Group on Drug Cardiotoxicity and Cardioprotection of the Italian Society of Cardiology","volume":"191","author":"Madonna","year":"2015","journal-title":"Int. J. Cardiol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/22\/6745\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:18:15Z","timestamp":1760145495000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/22\/6745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,15]]},"references-count":35,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["jcm11226745"],"URL":"https:\/\/doi.org\/10.3390\/jcm11226745","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,15]]}}}